Intravenous Immunoglobulin Market Growth to 7.3% CAGR by 2030 | Straits Research Insights

The global intravenous immunoglobulin (IVIG) market was valued at USD 11.17 billion in 2021 and is expected to reach USD 21.06 billion by 2030, growing at a CAGR of 7.3% during the forecast period (2022–2030). Intravenous immunoglobulin (IVIG) is a blood product derived from the plasma of healthy human donors. It contains concentrated antibodies that are used to treat a variety of autoimmune, inflammatory, and infectious diseases. IVIG therapy has been increasingly used for the treatment of immune deficiencies, chronic inflammatory conditions, and neurological disorders, which has contributed to its rapid market growth.

As the demand for IVIG therapies increases due to the growing prevalence of autoimmune disorders and primary immunodeficiencies, the market is expanding significantly. Additionally, the continued development of novel IVIG formulations and the rising awareness of its applications are expected to further drive the market's growth in the coming years.

Market Definition

The intravenous immunoglobulin (IVIG) market refers to the market for intravenous infusion therapies containing concentrated immunoglobulin (IgG) antibodies derived from pooled human plasma. IVIG is used in the treatment of various conditions, including immune deficiencies, autoimmune diseases, and certain neurological disorders. It works by modulating the immune system, offering both passive immunity and anti-inflammatory effects, making it vital for treating conditions such as primary immunodeficiency, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and more.

Market Segmentation

For Segmentation Click Here @ https://straitsresearch.com/report/intravenous-immunoglobulin-market/segmentation

Key Segmentation Categories

• By Type: Standard IVIG, Hyperimmune IVIG
• By Application: Primary Immunodeficiency, Autoimmune Disorders, Neurological Disorders, Others
• By End-User: Hospitals, Clinics, Home Care Settings, Others
• By Region: North America, Europe, Asia-Pacific, Middle East & Africa, South America

Highlights of Intravenous Immunoglobulin Market

1. The global IVIG market was valued at USD 11.17 billion in 2021 and is projected to reach USD 21.06 billion by 2030.
2. The market is expected to grow at a CAGR of 7.3% during the forecast period (2022–2030).
3. Increasing demand for IVIG in the treatment of autoimmune diseases and primary immunodeficiencies is driving market growth.
4. The growing use of IVIG in neurological disorders, such as Guillain-Barré syndrome and CIDP, is contributing to market expansion.
5. New advancements in IVIG formulations and the development of more effective therapies are expected to further fuel the market’s growth.

Key Players

• Grifols S.A.
• CSL Behring
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Baxter International Inc.
• Kedrion Biopharma Inc.
• Bio Products Laboratory Ltd.
• LFB S.A.
• Shanghai Raas Blood Products Co., Ltd.
• Human BioPlasma

Dominated Region: Asia-Pacific
Fastest Growing Region: Europe

For More Information or Query or Customization Before Buying, Visit @ https://straitsresearch.com/buy-now/intravenous-immunoglobulin-market

7 Questions Answered in the Report

1. What is the current size of the global intravenous immunoglobulin market?
2. What are the primary factors driving the growth of the IVIG market?
3. What are the key applications of intravenous immunoglobulin?
4. Which regions are expected to experience the highest growth in the IVIG market?
5. What are the challenges faced by the intravenous immunoglobulin market?
6. Who are the major players operating in the IVIG market?
7. What are the future trends and opportunities in the intravenous immunoglobulin market?

Regional Insights

• North America: North America holds the largest share of the IVIG market, primarily due to the high prevalence of autoimmune disorders and primary immunodeficiencies, along with well-established healthcare infrastructure. The U.S. is the largest market for IVIG products, with significant demand for immunodeficiencies treatment and neurological diseases.

• Europe: Europe is expected to be the fastest-growing region in the IVIG market, with increasing healthcare expenditure, rising demand for IVIG in autoimmune and neurological treatments, and improved access to advanced therapies. The presence of leading market players in Europe further supports this growth.

• Asia-Pacific: The Asia-Pacific region dominates the IVIG market due to the growing population, increasing awareness about immunodeficiencies, and rising demand for IVIG therapies in emerging economies such as China and India. Increased healthcare spending and improvements in healthcare infrastructure are also contributing to market growth.

For Full PDF Sample Copy of the Report
Get a Full PDF Sample Copy of the Report @ https://straitsresearch.com/report/intravenous-immunoglobulin-market/request-sample

Conclusion

The intravenous immunoglobulin market is witnessing robust growth, driven by the increasing prevalence of autoimmune diseases, primary immunodeficiencies, and neurological disorders. As new IVIG formulations continue to emerge and the understanding of its therapeutic benefits expands, the market is poised for continued expansion. North America currently dominates the IVIG market, while Europe is expected to experience the highest growth rate. With an increasing number of treatment options and improved patient access to therapies, the IVIG market is set to continue its upward trajectory, offering significant opportunities for market players and healthcare providers.

For Custom Report Click Here @ https://straitsresearch.com/buy-now/intravenous-immunoglobulin-market

Contact Us:
Email: sales@straitsresearch.com
Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)